A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, and 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis

Trial Profile

A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, and 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2013

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Fantasia Phase III
  • Sponsors Procter & Gamble; Warner Chilcott
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jan 2012 Results published in Osteoporosis International.
    • 20 Sep 2011 Results assessing bone safety presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top